CONTAIN NO CB

TSCA HEALTH & SAFETY STUDY COVER SHEET

*TSCA CBI STATUS: NONE CONTAIN NO CBI

RECEIVED OPPT CBIC
05 NOV 21 AM 10:54

1.0 SUBMISSION TYPE

☐ 8(d) **XX 8(e)** ☐ FYI ☐ 4 ☐ OTHER: Specify_____

XX- Initial Submission - Follow-up Submission ☐ Final Report Submission

Previous EPA Submission Number or Title if update or follow-up: Docket Number, if any: #

8EHQ-11105-16286

☐ continuation sheet attached

2.1 SUMMARY/ABSTRACT ATTACHED (may be required for 8(e): optional for §4, 8(d) & FYI)	**2.2 SUBMITTER TRACKING NUMBER OR INTERNAL ID**	**2.3 FOR EPA USE ONLY**
X- YES ☐ NO	**7004 2510 0002 4033 8537** 05-2-22	

3.0 CHEMICAL/TEST SUBSTANCE IDENTITY

CAS# : 75-44-5

Reported Chemical Name (specify nomenclature if other than CAS name):
Carbonyl Chloride

Purity ___%

X- Single Ingredient

☐ Commercial/Tech Grade

☐ Mixture *Trade Name* Phosgene *Common Name:* Carbonyl Chloride

Other chemical(s) present in tested mixture	*CAS Number*	*NAME*	*% WEIGHT*

☐ continuation sheet attached

RECEIVED OPPT NCIC
2005 NOV 29 AM 10:7

4.0 REPORT/STUDY TITLE

Acute head-only exposure of dogs to phosphene. Part III: Comparison of indicators of lung injury in dogs and rats.

Study No.: MS05-954

☐ continuation sheet attached

5.1 STUDY/TSCATS INDEXING TERMS

[CHECK ONE]

HEALTH EFFECTS (HE): X ENVIRONMENTAL EFFECTS (EE):____ ENVIRONMENTAL FATE (EF):____

5.2 STUDY/TSCATS INDEXING TERMS (see instructions for 4 digit codes)

STUDY TYPE: ATOX *Other:*____

SUBJECT ORGANISM (HE, EE): DOGS, RATS *Other:*____

ROUTE OF EXPOSURE (HE only):__ *Other:*____

VEHICLE OF EXPOSURE (HE only)_ *Other:*____

6.0 REPORT/STUDY INFORMATION ☐ Study is GLP

Laboratory Bayer HealthCare, 42096 Wuppertal, Germany Report/Study Date: 10/20/05

Source of Data/Study Sponsor (if different than submitter) Bayer Toxicology

☐ continuation sheet attached

7.0 SUBMITTER INFORMATION

Janet M. Mostowy, Ph.D.
Head of Product Safety & Regulatory Affairs
Bayer Material Science Corporation - 100 Bayer Road, Pittsburgh, PA. 15205
Phone: 412-777-3490

Technical Contact: **SAME AS ABOVE** Phone: ( )_____

☐ continuation sheet attached

8.0 ADDITIONAL/OPTIONAL STUDY COMMENTS

This compound is an intermediate/reactant for isocyanate production.

☐ continuation sheet attached

8EHQ-05-16286

Submitter Signature: _____ **Date: 11/16/05**

290484

9.0 CONTINUATION SHEET

Submitter Tracking Number/Internal ID

7004 2510 0002 4033 8537
05-2-22

Continuation of 2.1

Reporting was based on the following results:

Male and female dogs were exposed to 9, 16.5 or 35 mg/m3 for 30 minutes resulting in C x T products of 270, 495 and 1050 mg/m3-min. All dogs were sacrificed 24 hours post-exposure. Endpoints included clinical signs, lung weights, BAL fluid and cellular endpionts, arterial blood gases, and lung histopathology. No mortality was observed. Increased lung weights occurred at the highest dose. Changes in BAL parameters were observed at 495 (borderline) and 1050 mg/m3-min. Mild alteration of p02 was observed at the highest dose. Lungs appeared distended, dark red and edematous at the high dose. Histopathology revealed mild inflammatory response starting at 495 mg/m3-min, with more severe effects such as epithelial necrosis, hemorrhages and serofibrinous exudates at 1050 mg/m3-min.

This study presents data on new findings in dogs exposed to phosgene and also shows previously reported findings occurring at a lower C x T product than previously reported. The effects found at 1050 mg/m3-min such as changes in BAL parameters, and alteration in p02, could not be found in the published literature for dogs. Furthermore, increased lung weights, and the histopathology found at the same dose are shown to occur at a lower than previously reported dose for dogs. These findings together suggest significant pulmonary effects resulting from phosgene exposure.